When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns ...

Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 ...

Buying $100 In AMGN: If an investor had bought $100 of AMGN stock 15 years ago, it would be worth $739.18 today based on a price of $379.40 for AMGN at the time of writing.

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Amgen Inc. has reached a significant milestone as its stock hit an all-time high of 385.63 USD, with shares currently trading at $386.08, just shy of the 52-week high of $385.12. This achievement ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.

Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them ...

Compared to the aggregate P/E ratio of the 83.91 in the Biotechnology industry, Amgen Inc. has a lower P/E ratio of 26.69. Shareholders might be inclined to think that the stock might perform worse ...